Firstline treatment and maintenance in newly diagnosed multiple myeloma patients

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 189-206

  Roussel, Murielle ^a   Facon, Thierry ^b   Moreau, Philippe ^c   Harousseau, Jean Luc ^d   Attal, Michel ^a  

^a CHU PURPAN   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d Boulevard Jacques Monod   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTHRACYCLINE; ANTICOAGULANT AGENT; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AGING; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; INFECTION; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; STANDARD OF CARE; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79955603395     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_9     Document Type: Review

References (67)

1. Alexanian R et al (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208(9):1680-1685
2. Alexanian R et al (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33(2):86-89 (Pubitemid 20040083)
3. Alexanian R et al (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80(4):887-890
4. Attal M et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma Intergroupe Francais du Myelome. N Engl J Med 335(2):91-97 (Pubitemid 26240110)
5. Attal M et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289-3294
6. Attal M et al (2010) Lenalidomide maintenance after transplantation for myeloma. ASCO Meeting Abstracts 28:8018
7. Barlogie B et al (2006a) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929-936 (Pubitemid 46638847)
8. Barlogie B et al (2006b) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021-1030 (Pubitemid 43357806)
9. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336(23):1657-1664
10. Berenson JR et al (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99(9):3163-3168 (Pubitemid 34525294)
11. Bjorkstrand B et al (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27(5):511-515 (Pubitemid 32266501)
12. Blade J et al (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106(12):3755-3759 (Pubitemid 41739009)
13. Cavo M et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1):35-39 (Pubitemid 40967171)
14. Cavo M et al (2009) A phase III study of double autotransplantation incorporating bortezomibthalidomide-dexamethasone (VTD) or thalidomide- dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD. ASH Annual Meeting Abstracts 114(22):351
15. Child JA et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875-1883 (Pubitemid 36532313)
16. Cunningham D et al (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 102(2):495-502 (Pubitemid 28346591)
17. Facon T et al (2006) Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107(4):1292-1298 (Pubitemid 43242361)
18. Facon T et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594):1209-1218 (Pubitemid 47516593)
19. Fermand JP et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9):3131-3136
20. Fermand JP et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23(36):9227-9233
21. Fritz E, Ludwig H (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11(11):1427-1436
22. Harousseau JL et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91(11):1498-1505
23. Harousseau JL et al (2008) Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol (Meeting Abstracts) 26(15 suppl):8505
24. Harousseau JL et al (2009) High complete and very good partial response rates with bortezomib - dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial. ASH Annual Meeting Abstracts 114(22):353
25. Harousseau JL et al (2010) Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study. ASCO Meeting Abstracts 28:8014
26. Hernandez JM et al (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127(2):159-164 (Pubitemid 39371808)
27. Hulin C et al (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27(22):3664-3670
28. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749-757
29. Kapoor P et al (2009) Melphalan and prednisone (MP) versus melphalan, prednisone and thalidomide (MPT) as initial therapy for previously untreated elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis of randomized controlled trials. ASH Annual Meeting Abstracts 114(22):615
30. Khan ML et al (2010) A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma. ASCO Meeting Abstracts 28:8131
31. Knop S et al (2009) Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: results of an interim analysis of the German DSMM Xia trial. J Clin Oncol (Meeting Abstracts) 27(15S):8516
32. Kumar S et al (2009) Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, Phase 2 EVOLUTION study. ASH Annual Meeting Abstracts 114(22):127
33. Ladetto M et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077-2084
34. Lane SW et al (2005) Role of VAD in the initial treatment of multiple myeloma. Blood 106(10):3674; author reply 3674-3675 (Pubitemid 41609211)
35. Lokhorst HM et al (2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6):1113-1120
36. Ludwig H et al (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113(15):3435-3442
37. Ludwig H et al (2010) Phase II study of bortezomib, thalidomide, and dexamethasone +/- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD EHA Meeting Abstracts 0371
38. McCarthy PL et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts 28:8017
39. Macro M et al (2006) Dexamethasone + Thalidomide (Dex/Thal) Compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. ASH Annual Meeting Abstracts 108(11):57
40. Mandelli F et al (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322(20):1430-1434 (Pubitemid 20152529)
41. Mateos MV et al (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108(7):2165-2172
42. Mateos M-V et al (2009) A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. ASH Annual Meeting Abstracts 114(22):3
43. Morgan GJ et al (2007) Thalidomide combinations improve response rates; results from the MRC IX study. ASH Annual Meeting Abstracts 110(11):3593
44. Morgan GJ et al (2009) The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. ASH Annual Meeting Abstracts 114(22):352
45. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16(12):3832-3842
46. Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113(4):1020-1034
47. Palumbo A et al (2005) Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 104(7):1428-1433 (Pubitemid 41356158)
48. Palumbo A et al (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25(28):4459-4465 (Pubitemid 350063804)
49. Palumbo A et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414-423 (Pubitemid 351255436)
50. Palumbo A et al (2009) Bortezomib, melphalan, prednisone and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide for initial treatment of elderly multiple myeloma patients. ASH Annual Meeting Abstracts 114(22):128
51. Palumbo A et al (2010a) A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. EHA Meeting Abstract 2010:566
52. 2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients. ASCO Meeting Abstracts 28:8015
53. Rajkumar SV et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431-436 (Pubitemid 46630462)
54. Rajkumar SV et al (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26(13):2171-2177
55. Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29-37
56. Reeder CB et al (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23(7):1337-1341
57. Reeder CB et al (2010) Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115(16):3416-3417
58. Richardson PG et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679-686
59. Rosinol L et al (2007) Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 25(28):4452-4458 (Pubitemid 350013852)
60. Rosinol L et al (2009). Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade)a/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcadea as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. ASH Annual Meeting Abstracts 114(22):130
61. San Miguel JF et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917
62. Sonneveld P et al (2008) First analysis of HOVON-65/GMMG-HD4 randomized Phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 112(11):653
63. Spencer A et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788-1793
64. Waage A et al (2010a) MP versus MPT for previously untreated elderly patients with multiple myeloma: a meta-analysis of 1,682 individual patient data from six randomized clinical trials. ASCO Meeting Abstracts 28:8130
65. Waage A et al (2010b) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9):1405-1412
66. Wijermans P et al (2008) Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. ASH Annual Meeting Abstracts 112(11):649
67. Zonder JA et al (2007) Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Annual Meeting Abstracts 110(11):77